MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00535-025-02211-5

Медицинская библиотека · Journal of gastroenterology · 2025

Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.

Kosaka Masanari, Fujino Hatsue, Tsuge Masataka, Yamaoka Kenji, Fujii Yasutoshi, Uchikawa Shinsuke, Ono Atsushi, Murakami Eisuke, Kawaoka Tomokazu, Miki Daiki, Hayes Clair Nelson, Kashiyama Seiya, Mokuda Sho, Yamazaki Shinichi, Oka Shiro

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).

METHODS

We studied 87 CHB patients with serum HBV DNA levels ≥ 5.0 log IU/mL who initiated entecavir (ETV) treatment between 2000 and 2018. Serum HBV RNA levels were measured at three-time points: before ETV treatment, at 12 weeks, and at 48 weeks after starting ETV treatment. Clinical markers associated with the antiviral effects of ETV treatment were analyzed.

RESULTS

Serum HBV RNA levels decreased in both HBeAg-positive and -negative patients during the observation period. In HBeAg-positive patients, multivariable analysis showed that lower HBV RNA levels at 48 weeks of ETV treatment were independently associated with HBeAg seroconversion. Additionally, lower baseline HBV RNA levels significantly predicted virologic response in those patients. In contrast, among HBeAg-negative patients, lower HBV core-related antigen (HBcrAg) levels and the FIB-4 index were independently associated with virologic response. In HBeAg-positive patients, those with higher baseline HBV RNA levels showed a more significant reduction in hepatitis B surface antigen levels.

CONCLUSION

Serum HBV RNA levels predicted HBeAg seroconversion and early HBV DNA reduction in HBeAg-positive patients, while HBcrAg was significantly associated with virologic response in HBeAg-negative patients. These findings highlight the different predictive roles of HBV RNA and HBcrAg based on HBeAg status, which may provide individualized treatment strategies.

Для цитирования: Kosaka Masanari, Fujino Hatsue, Tsuge Masataka, Yamaoka Kenji, Fujii Yasutoshi, Uchikawa Shinsuke, Ono Atsushi, Murakami Eisuke, Kawaoka Tomokazu, Miki Daiki, Hayes Clair Nelson, Kashiyama Seiya, Mokuda Sho, Yamazaki Shinichi, Oka Shiro. Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.. Journal of gastroenterology. 2025. DOI: 10.1007/s00535-025-02211-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.